These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 1617509

  • 1. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
    Goel V, Naylor CD.
    Can J Cardiol; 1992; 8(1):31-8. PubMed ID: 1617509
    [Abstract] [Full Text] [Related]

  • 2. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL.
    N Engl J Med; 1995 May 25; 332(21):1418-24. PubMed ID: 7723799
    [Abstract] [Full Text] [Related]

  • 3. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R, Fattore G, Gensini G.
    G Ital Cardiol; 1997 Jul 25; 27(7):721-6. PubMed ID: 9303862
    [Abstract] [Full Text] [Related]

  • 4. Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries.
    Cox JL, Lee E, Langer A, Armstrong PW, Naylor CD.
    CMAJ; 1997 Feb 15; 156(4):497-505. PubMed ID: 9054819
    [Abstract] [Full Text] [Related]

  • 5. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W, Pierre K, Massel D.
    Can J Cardiol; 2005 Apr 15; 21(5):423-31. PubMed ID: 15861260
    [Abstract] [Full Text] [Related]

  • 6. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
    Massel D.
    Can J Cardiol; 1999 Feb 15; 15(2):173-9. PubMed ID: 10079776
    [Abstract] [Full Text] [Related]

  • 7. Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I.
    Kaul P, Armstrong PW, Chang WC, Naylor CD, Granger CB, Lee KL, Peterson ED, Califf RM, Topol EJ, Mark DB.
    Circulation; 2004 Sep 28; 110(13):1754-60. PubMed ID: 15381645
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy.
    Lessler DS, Avins AL.
    Arch Intern Med; 1992 Aug 28; 152(8):1665-72. PubMed ID: 1497400
    [Abstract] [Full Text] [Related]

  • 13. [Comparison of the cost effectiveness of treatment of acute myocardial infarct with primary angioplasty and thrombolysis ].
    Golán L, Simek S, Linhart A, Cahlík T, Palecek T, Lubanda JC, Korínek J, Beran S, Aschermann M.
    Vnitr Lek; 2003 Feb 28; 49(2):97-102. PubMed ID: 12728575
    [Abstract] [Full Text] [Related]

  • 14. Outcome of thrombolytic therapy in relation to hospital size and invasive cardiac services. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
    Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Moulopoulos S, Paolasso EA, Van der Werf T.
    Arch Intern Med; 1994 Oct 10; 154(19):2237-42. PubMed ID: 7944845
    [Abstract] [Full Text] [Related]

  • 15. Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction.
    Antioch KM, Jennings G, Botti M, Chapman R, Wulfsohn V.
    Eur J Health Econ; 2002 Oct 10; 3(1):26-39. PubMed ID: 15609115
    [Abstract] [Full Text] [Related]

  • 16. Thrombolytic therapy in acute coronary thrombosis.
    Ramalanjaona GR, Mathew JC.
    Indiana Med; 1990 Jun 10; 83(6):410-2. PubMed ID: 2112180
    [Abstract] [Full Text] [Related]

  • 17. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R, Pagano D, Mazzotta G, Rosen SD, Fattore G, De Caterina R, Gensini G.
    Eur Heart J; 1998 Oct 10; 19(10):1518-24. PubMed ID: 9820990
    [Abstract] [Full Text] [Related]

  • 18. Primary PTCA versus thrombolysis with tPA in acute myocardial infarction: a formal cost-effectiveness analysis.
    Müllner M, Paulis M, Nikfardjam M, Domanovits H, Huber K.
    Wien Klin Wochenschr; 1999 Jan 15; 111(1):37-41. PubMed ID: 10067269
    [Abstract] [Full Text] [Related]

  • 19. Streptokinase and tissue plasminogen activator in acute myocardial infarction.
    Brewer CC, Markis JE.
    Heart Lung; 1986 Nov 15; 15(6):552-8. PubMed ID: 3095269
    [Abstract] [Full Text] [Related]

  • 20. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
    Kent DM, Hayward RA, Griffith JL, Vijan S, Beshansky JR, Califf RM, Selker HP.
    Am J Med; 2002 Aug 01; 113(2):104-11. PubMed ID: 12133748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.